试点:唾液中乳酸作为阿尔茨海默氏症疾病的生物标志物
B L Hammerschlag1, B Butts1, Kds Likos1
1Emory University, Atlanta, Georgia, USA.
medRxiv : the preprint server for health sciences
|November 28, 2024
概括
唾液中乳酸 (sLF) 显示出作为早期阿尔茨海默病 (AD) 生物标志物的潜力. 这项试点研究发现sLF与记忆和视觉空间能力相关,这是早期AD的关键指标.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 研究寻找早期生物标志物用于病理检测.
- 唾液中乳酸 (Lf) 是一种结合铁的葡萄糖蛋白,存在于生物液体中,与阿尔茨海默症症状有关.
研究的目的:
- 调查唾液中乳酸 (sLF) 作为阿尔茨海默病 (AD) 的潜在早期生物标志物.
主要方法:
- 收集了来自中年至老年成年人患阿尔茨海默病风险的唾液样本.
- 进行认知测试,评估记忆,执行功能和视觉空间能力.
- 研究了SLF度和认知表现之间的关系.
主要成果:
- 在sLF水平和数字跨度记忆测试得分之间发现了显著的相关性.
- 在sLF和心理旋转测试得分之间观察到温和的相关性.
- 在种族群体之间发现的平均sLF度没有显著差异.
结论:
- Salivary lactoferrin (sLF) 可能与与阿尔茨海默病相关的早期认知变化相关,例如记忆和视觉空间下降.
- 对不同人群进行更大的纵向研究是必要的,以验证sLF作为AD的临床生物标志物.
相关概念视频
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165